KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Gsk (GSK) Gross Margin (2016 - 2026)

Gsk has reported Gross Margin over the past 18 years, most recently at 75.42% for Q1 2026.

  • For Q1 2026, Gross Margin rose 119.0% year-over-year to 75.42%; the TTM value through Mar 2026 reached 72.69%, down 1.0%, while the annual FY2025 figure was 72.4%, 123.0% up from the prior year.
  • Gross Margin for Q1 2026 was 75.42% at Gsk, up from 69.17% in the prior quarter.
  • Over five years, Gross Margin peaked at 75.42% in Q1 2026 and troughed at 62.21% in Q1 2022.
  • A 5-year average of 71.17% and a median of 72.57% in 2023 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: plummeted -570bps in 2022 and later surged 984bps in 2023.
  • Year by year, Gross Margin stood at 65.34% in 2022, then grew by 11bps to 72.57% in 2023, then rose by 1bps to 73.16% in 2024, then fell by -5bps to 69.17% in 2025, then grew by 9bps to 75.42% in 2026.
  • Business Quant data shows Gross Margin for GSK at 75.42% in Q1 2026, 69.17% in Q4 2025, and 73.58% in Q3 2025.